The relationship between inspiratory lung function parameters and airway hyper-responsiveness in subjects with mild to moderate COPD

BMC Research Notes

Yvonne F Heijdra¹  P N Richard Dekhuijzen¹  Bas Staffhorst²  Wim C J Hop²  Frank J Visser³  Sunil K Ramlal⁴ 

[1] Dept. of Pulmonology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands;Dept. of Biostatistics, Erasmus Medical Centre, Rotterdam, The Netherlands;Dept. of Pulmonology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands;Dept. of Pulmonology, IJsselland Ziekenhuis, 2900 AR, Capelle a/d IJssel, 690, The Netherlands

关键词: Visual analogue scale;    Inspiratory lung functions parameters;    Forced expiratory volume 1 second;    Chronic obstructive pulmonary disease;   

Others  :  1166471
DOI  :  10.1186/1756-0500-5-209

 received in 2012-01-09, accepted in 2012-04-04,  发布年份 2012

【 摘 要 】

Background

The aim of this study was to evaluate the effects of increasing doses of inhaled histamine on the forced expiratory volume in one second (FEV₁), inspiratory lung function parameters (ILPs) and dyspnea in subjects with mild to moderate chronic obstructive pulmonary disease (COPD)

Methods

Thirty-nine (27 males and 12 females) stable COPD patients (GOLD stages I and II) inhaled a maximum of six sequential doses of histamine according to ERS standards until one of these provocative doses produced a 20% decrease in FEV₁ (PD₂₀). The effects on the FEV₁, the forced inspiratory volume in one second (FIV₁), inspiratory capacity (IC), forced inspiratory flow at 50% of the vital capacity (FIF50), peak inspiratory flow (PIF) and dyspnea score by a visual analogue scale (VAS) were measured and investigated after each dose step

Results

After each dose of histamine, declines in all of the lung function parameters were detected; the largest decrease was observed in the FEV₁. At the PD₂₀ endpoint, more FEV₁ responders than ILP responders were found. Among the ILPs, the FIV₁ and IC best predicted which patients would reach the PD₂₀ endpoint. No significant correlations were found between any of the lung function parameters and the VAS results

Conclusions

In COPD patients, the FEV₁ and ILPs declined after each dose of inhaled histamine. FEV₁ was more sensitive to histamine than the ILPs. Of the ILPs, FIV₁ and IC were the best predictors of reaching the PD₂₀ endpoint. No statistically significant correlations were found between the lung function parameters and the degree of dyspnea

【 授权许可】

   
2012 Ramlal et al.; licensee BioMed Central Ltd

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Sterk PJ, Fabbri LM, Quanjer P, Cockcroft DW: Airway responsiveness: standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993, 6(Suppl 16):53-83.
• [2]Yan K, Salome CM, Woolcock AJ: Prevalence and nature of bronchial hyperresponsiveness in subjects with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985, 132:25-29.
• [3]Tashkin DP, Altose MD, Bleecker ER: The Lung Health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis 1992, 145:301-310.
• [4]Dayman H: Mechanics of airflow in health and emphysema. J Clin Invest 1951, 3031:1175-1190.
• [5]Postma DS, De Vries K, Koëter GH: Independent influence of reversibility of airflow obstruction and non-specific hyperreactivity on the long-term course of lung function in chronic airflow obstruction. Am Rev Respir Dis 1986, 134:176-180.
• [6]Sterk PJ, Bel EH: Bronchial hyperresponsiveness: the need for a distinction between hypersensitivity and excessive airway narrowing. Eur Respir J 1989, 2:267-274.
• [7]Moreno RH, Hogg JC, Pare PD: Mechanics of airway narrowing. Am Rev Respir Dis 1986, 133:1171-1180.
• [8]Petty TL, Silvers GW, Stanford RE: Mild emphysema is associated with reduced elastic recoil and increased lung size but not with air-flow limitation. Am Rev Respir Dis 1987, 136:867-871.
• [9]Taube C, Lehnigk B, Paasch K: Factor analysis of changes in dyspnoea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163:1256-1276.
• [10]American Thoracic Society Subcommittee Statement on Bronchial Inhalation Challenges Am Thoracic Soc News Springs 1980, 11-19.
• [11]Pauwels RA, Buist AS, Calverely PMA, Jenkens CR, Hurd SS: Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
• [12]Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zeilinski J, Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management and prevention of COPD (2008 Updated). www.goldcopd.org webcite
• [13]Pellegrino R, Viegi G, Brusasco V: ATS/ERS Task Force: standardisation of lung function testing. Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-968.
• [14]Siafakas NM, Vermeire P, Pride NB, Paoletti , Gibson J, Howard P: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995, 8:1398-1420.
• [15]Visser F, Ramlal SK, Janssen J, Dekhuijzen R, Heijdra Y: Do we need slow or forced expiration before the FIV1 measurement? Eur Respir J 2005, 26(Suppl. 49):120s.
• [16]Hadcroft J, Calverly PM: Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001, 56:713-720.
• [17]Quanjer PH, Tammeling GJ: Standardized lung function testing. Official statement of the ERS. Eur Respir J 1993, 6(Suppl 16):5-40.
• [18]Langley SJ, Goldthorpe S, Craven M, Woodcock A, Custovic A: Relationship between exposure to domestic allergens and bronchial hyperresponsiveness in non-sensitised, atopic asthmatic subjects. Thorax 2005, 60:17-21.
• [19]Visser F, Ramlal SK, Dekhuijzen R, Heijdra Y: Random variation of inspiratory lung function parameters in patients with COPD: a diagnostic accuracy study. BMC Pulm Med 2010, 10:28. BioMed Central Full Text
• [20]Ramlal SK, Visser F, Hop W, Dekhuijzen R, Heijdra Y: Reversibility of inspiratory lung function parameters after short-term bronchodilators in COPD. Respir Physiol Neurobiol 2010, 173:58-63.
• [21]Kanner RE, Connett JE, Altose MD: Gender difference in airway hyperresponsiveness in smokers with mild to moderate airflow limitation: the lung health study. Am J Respir Crit Care Med 1994, 150:956-961.
• [22]Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee W, Wise RA: for the Lung Health Study Research Group: methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996, 153:1802-1811.
• [23]Taube C, Einhaus M, Welker L, Holz O, Branscheid D: Isolated bronchi of patients with COPD show decreased histamine responsiveness compared to smokers with normal lung function. COPD 2006, 3:25-31.
• [24]Van Overveld FJ, Houben LAM, Terpstra GK: Patients with chronic bronchitis differ in their mast cell subtypes as compared with normal subjects. Agents Actions 1989, 26:60-62.
• [25]Bagnato GF, Gulli S, Giacobbe O, De Pasquale R: Bronchial hyperresponsiveness in subjects with gastroesophageal reflux. Respiration 2000, 67:507-509.
• [26]Shim CS, Williams MH: Aerosol beclomethasone in patients with steroid-responsive chronic obstructive pulmonary disease. Am J Med 1985, 78:655-668.
• [27]Jarad NA, Wedzicha JA, Burge PS, Calverley PM: An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999, 93:161-166.
• [28]Taube C, Lehnigk B, Paasch K, Kirsten DK: Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:216-220.
• [29]Noseda A, Schmerber J, Prigogine T: Perceived effect on shortness of breath of an acute inhalation of saline or terbutaline: variability and sensitivity of a visual analogue scale in patients with asthma or COPD. Eur Respir J 1992, 5:1043-1053.
• [30]Noseda A: Dyspnoea and perception of airway obstruction. Rev Mal Respir 2003, 20:364-372.